Hereditary Angioedema R&D Pipeline Analysis Report, Q4 2020
Hereditary Angioedema Pipeline Overview
The Q4 Hereditary Angioedema pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under development for Hereditary Angioedema, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Hereditary Angioedema Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Hereditary Angioedema disease overview, Hereditary Angioedema types, Hereditary Angioedema symptoms, causes, and FDA/EMA approved treatment options.
Hereditary Angioedema Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Hereditary Angioedema indication. The report presents near-term and long-term pipeline development trends and potential insights.
Hereditary Angioedema Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 18 companies. Business profiles and contact details of the companies actively perusing Hereditary Angioedema pipeline are assessed.
Hereditary Angioedema R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Hereditary Angioedema discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Hereditary Angioedema companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Hereditary Angioedema pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Hereditary Angioedema Pipeline Market News and Developments during 2020
The Hereditary Angioedema industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Hereditary Angioedema Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
The Q4 Hereditary Angioedema pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under development for Hereditary Angioedema, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Hereditary Angioedema Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Hereditary Angioedema disease overview, Hereditary Angioedema types, Hereditary Angioedema symptoms, causes, and FDA/EMA approved treatment options.
Hereditary Angioedema Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Hereditary Angioedema indication. The report presents near-term and long-term pipeline development trends and potential insights.
Hereditary Angioedema Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 18 companies. Business profiles and contact details of the companies actively perusing Hereditary Angioedema pipeline are assessed.
Hereditary Angioedema R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Hereditary Angioedema discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Hereditary Angioedema companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Hereditary Angioedema pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Hereditary Angioedema Pipeline Market News and Developments during 2020
The Hereditary Angioedema industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Hereditary Angioedema Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
- Hereditary Angioedema pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 18 companies are included including Adverum Biotechnologies Inc, Attune Pharmaceuticals, BioCryst Pharmaceuticals Inc, BioMarin Pharmaceutical Inc, Cevec Pharmaceuticals GmbH, CSL Ltd, Generium Pharmaceuticals, iBio Inc, Intellia Therapeutics Inc, Ionis Pharmaceuticals Inc, Kalvista Pharmaceuticals Inc, Octapharma AG, Pharming Group NV, Pharvaris BV, RegenxBio Inc, Serpinx BV, Takeda Pharmaceutical Co Ltd (Shire Plc), Verseon Corp,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in Hereditary Angioedema pipeline market
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
- Develop new candidates based on most focused targets and mechanism of actions
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. HEREDITARY ANGIOEDEMA PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Hereditary Angioedema Pipeline, 2020
2.2 Most focused Mechanism of Action in Hereditary Angioedema Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Hereditary Angioedema pipeline
2.5 Active Companies Developing Hereditary Angioedema pipeline
3. HEREDITARY ANGIOEDEMA DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. HEREDITARY ANGIOEDEMA PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Adverum Biotechnologies Inc
Attune Pharmaceuticals
BioCryst Pharmaceuticals Inc
BioMarin Pharmaceutical Inc
Cevec Pharmaceuticals GmbH
CSL Ltd
Generium Pharmaceuticals
iBio Inc
Intellia Therapeutics Inc
Ionis Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc
Octapharma AG
Pharming Group NV
Pharvaris BV
RegenxBio Inc
Serpinx BV
Takeda Pharmaceutical Co Ltd (Shire Plc)
Verseon Corp
5. HEREDITARY ANGIOEDEMA PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. HEREDITARY ANGIOEDEMA PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2. HEREDITARY ANGIOEDEMA PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Hereditary Angioedema Pipeline, 2020
2.2 Most focused Mechanism of Action in Hereditary Angioedema Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Hereditary Angioedema pipeline
2.5 Active Companies Developing Hereditary Angioedema pipeline
3. HEREDITARY ANGIOEDEMA DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. HEREDITARY ANGIOEDEMA PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Adverum Biotechnologies Inc
Attune Pharmaceuticals
BioCryst Pharmaceuticals Inc
BioMarin Pharmaceutical Inc
Cevec Pharmaceuticals GmbH
CSL Ltd
Generium Pharmaceuticals
iBio Inc
Intellia Therapeutics Inc
Ionis Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc
Octapharma AG
Pharming Group NV
Pharvaris BV
RegenxBio Inc
Serpinx BV
Takeda Pharmaceutical Co Ltd (Shire Plc)
Verseon Corp
5. HEREDITARY ANGIOEDEMA PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. HEREDITARY ANGIOEDEMA PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
